PIK3CD (O00329) variants and mutations
PIK3CD (also known as O00329) is a human protein-coding gene encoding a phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform protein. Its p110-delta activity generates PIP3 primarily in leukocytes and is essential for antigen-receptor and cytokine signaling. Heterozygous activating variants cause activated PI3K-delta syndrome type 1 with immunodeficiency, lymphoproliferation, and immune dysregulation. This analysis covers 1,087 PIK3CD variants and mutations. Of these, 78% have computational variant effect predictions. Disease context includes activated PI3K-delta syndrome, immunodeficiency 14b, autosomal recessive, and Combined immunodeficiency with facio-oculo-skeletal anomalies. Example PIK3CD variants include M1?, P2L, and P2T.
Variant analysis overview
- Gene: PIK3CD
- Protein: O00329
- UniProt accession: O00329
- Organism: Homo sapiens
- Variants analyzed: 1087
- Variant scope: all variants
- Completed: 2026-08-18
Variant and mutation evidence
- Variant composition: 827 unspecified-consequence records; 113 missense variants; 124 synonymous variants; 3 splice-region variants; 13 frameshift variants; 2 in-frame deletions; 2 stop-gained variants; 3 substitution
- Prediction scores: 851 variants have prediction scores (78% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: activated PI3K-delta syndrome, immunodeficiency 14b, autosomal recessive, Combined immunodeficiency with facio-oculo-skeletal anomalies, B-cell chronic lymphocytic leukemia, combined immunodeficiency with faciooculoskeletal anomalies, follicular lymphoma, neoplasm, non-Hodgkin lymphoma, neoplasm of mature B-cells, marginal zone lymphoma, combined immunodeficiency, severe combined immunodeficiency.
Protein structure and variant hotspots
- Protein features: 5 domains; 2 post-translational modification sites.
- Structural context: 750 variants have structural context.
- PTM context: 2 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable PIK3CD variants
Examples include M1?, P2L, P2T, P2S, P3A, P3L, P3S, P3P. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, NCI-TCGA Cosmic COSV6312, cosmic curated COSV63127, Variant assessed as somatic; high impact.
- P2L (p.Pro2Leu), rs1257745660, ClinGen CA338299362, ClinVar RCV001213350, ClinVar RCV005235533, REVEL 0.07, CADD 23.10, Uncertain significance, Immunodeficiency 14
- P2T (p.Pro2Thr), rs541082914, ClinGen CA576757, ClinVar RCV001475518, 1000Genomes rs541082914, REVEL 0.17, CADD 23.60, Likely benign
- P2S (p.Pro2Ser), gnomAD 1-9710459-C-T, REVEL 0.18, CADD 23.80
- P3A (p.Pro3Ala), ExAC rs750425882, TOPMed rs750425882, gnomAD rs750425882, REVEL 0.54, CADD 24.20
- P3L (p.Pro3Leu), rs780051553, ClinGen CA576761, cosmic curated COSV63131, ClinVar RCV001897857, REVEL 0.51, CADD 25.70, Uncertain significance
- P3S (p.Pro3Ser), cosmic curated COSV63131, ExAC rs750425882, TOPMed rs750425882, gnomAD rs750425882, REVEL 0.57, CADD 24.80
- P3P (p.Pro3Pro), gnomAD 1-9710464-T-G, CADD 1.48
- V5L (p.Val5Leu), gnomAD 1-9710468-G-T, REVEL 0.07, CADD 21.80
- D6A (p.Asp6Ala), rs749032083, ClinGen CA17769061, ClinVar RCV001318415, ExAC rs749032083, REVEL 0.09, CADD 22.20, Uncertain significance
- D6E (p.Asp6Glu), rs1037340766, NCI-TCGA Cosmic COSV1007, cosmic curated COSV10074, TOPMed rs1037340766, AlphaMissense 0.11, MetaLR 0.09, Variant assessed as somatic; moderate impact.
- D6G (p.Asp6Gly), rs749032083, ClinGen CA576762, ClinVar RCV001308996, ClinVar RCV004691409, REVEL 0.05, CADD 22.80, Uncertain significance
- D6N (p.Asp6Asn), TOPMed rs879660382, REVEL 0.09, CADD 22.40
- D6H (p.Asp6His), gnomAD 1-9710471-G-C, REVEL 0.09, CADD 22.60
- D6V (p.Asp6Val), gnomAD 1-9710472-A-T, REVEL 0.23, CADD 22.50
- C7R (p.Cys7Arg), ExAC rs772424669, TOPMed rs772424669, gnomAD rs772424669, REVEL 0.29, CADD 23.00
- C7Y (p.Cys7Tyr), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10074, Variant assessed as somatic; moderate impact.
- P8P (p.Pro8Pro), rs145290703, gnomAD 1-9710479-C-A, CADD 10.20
- M9T (p.Met9Thr), gnomAD 1-9710481-T-C, REVEL 0.20, CADD 23.00
- E10D (p.Glu10Asp), rs867168019, ClinGen CA17769102, ClinVar RCV003076788, ClinVar RCV003404045, REVEL 0.17, CADD 13.40, Uncertain significance, Immunodeficiency 14; Inborn genetic diseases; PIK3CD-related disorder
- E10K (p.Glu10Lys), 1000Genomes rs200039969, ExAC rs200039969, gnomAD rs200039969, REVEL 0.34, CADD 24.70
- T13N (p.Thr13Asn), gnomAD 1-9710493-C-A, REVEL 0.05, CADD 20.20
- T13T (p.Thr13Thr), rs771088388, gnomAD 1-9710494-C-G, CADD 10.50
- K14T (p.Lys14Thr), rs1647002482, ClinGen CA338299437, ClinVar RCV001240756, Ensembl rs1647002482, AlphaMissense 0.09, MetaLR 0.16, Uncertain significance
- K14E (p.Lys14Glu), gnomAD 1-9710495-A-G, REVEL 0.14, CADD 18.90
- N17S (p.Asn17Ser), gnomAD 1-9710505-A-G, REVEL 0.03, CADD 14.10
- N17N (p.Asn17Asn), rs1450081579, gnomAD 1-9710506-T-C, CADD 5.82
- S19G (p.Ser19Gly), TOPMed rs1185347441
- S19R (p.Ser19Arg), ESP rs376606452, ExAC rs376606452, TOPMed rs376606452, gnomAD rs376606452, REVEL 0.04, CADD 7.33, Likely benign
- S19S (p.Ser19Ser), rs376606452, gnomAD 1-9710512-C-T, CADD 6.07
- V20I (p.Val20Ile), rs143116020, ClinGen CA576768, cosmic curated COSV63127, ClinVar RCV001904388, REVEL 0.11, CADD 17.70, Uncertain significance
- V20F (p.Val20Phe), gnomAD 1-9710513-G-T, REVEL 0.51, CADD 25.60
- V21A (p.Val21Ala), rs770275584, ClinGen CA576769, ClinVar RCV002047379, ClinVar RCV005453348, REVEL 0.05, CADD 5.16, Likely benign
- V21M (p.Val21Met), gnomAD 1-9710516-G-A, REVEL 0.07, CADD 16.50
- V22I (p.Val22Ile), ExAC rs775849617, gnomAD rs775849617, REVEL 0.10, CADD 21.90
- D23D (p.Asp23Asp), rs1371234745, gnomAD 1-9710524-C-T, CADD 10.70
- F24F (p.Phe24Phe), gnomAD 1-9710527-C-T, CADD 12.30
- L25L (p.Leu25Leu), gnomAD 1-9710530-G-A, CADD 10.40
- L26L (p.Leu26Leu), rs2100769556, gnomAD 1-9710531-C-T, CADD 10.10
- L26M (p.Leu26Met), gnomAD 1-9710531-C-A, REVEL 0.38, CADD 22.50
- P27P (p.Pro27Pro), gnomAD 1-9710536-C-T, CADD 10.60
- G29G (p.Gly29Gly), rs763238685, gnomAD 1-9710542-G-A, CADD 8.85
- V30I (p.Val30Ile), TOPMed rs1382575108, gnomAD rs1382575108, REVEL 0.07, CADD 13.50
- Y31F (p.Tyr31Phe), ExAC rs763687876
- L32V (p.Leu32Val), gnomAD rs1046472589, REVEL 0.18, CADD 14.30, Uncertain significance, Immunodeficiency 14
- F34L (p.Phe34Leu), TOPMed rs1647004121, Uncertain significance, Immunodeficiency 14
- P35R (p.Pro35Arg), gnomAD rs1279930246, REVEL 0.15, CADD 22.30, Pathogenic
- P35P (p.Pro35Pro), rs1311974494, gnomAD 1-9710560-T-G, CADD 0.90
- V36L (p.Val36Leu), gnomAD 1-9710561-G-C, REVEL 0.49, CADD 26.10
- V36V (p.Val36Val), rs1231783212, gnomAD 1-9710563-G-A, CADD 9.51
- R38C (p.Arg38Cys), rs765729544, ClinGen CA576774, ClinVar RCV000814653, ClinVar RCV002534844, REVEL 0.24, AlphaMissense 0.08, Likely benign, Immunodeficiency 14
- R38H (p.Arg38His), rs761349863, NCI-TCGA Cosmic COSV6313, cosmic curated COSV63130, ExAC rs761349863, REVEL 0.51, CADD 24.20, Uncertain significance, Immunodeficiency 14
- R38L (p.Arg38Leu), rs761349863, ClinGen CA338299595, ClinVar RCV003042365, ClinVar RCV005254671, REVEL 0.39, CADD 22.60, Uncertain significance, Immunodeficiency 14
- R38P (p.Arg38Pro), ExAC rs761349863, TOPMed rs761349863, gnomAD rs761349863, REVEL 0.51, CADD 23.00, Uncertain significance
- R38S (p.Arg38Ser), rs765729544, ClinGen CA338299592, ClinVar RCV003743217, AlphaMissense 0.08, MetaLR 0.21, Uncertain significance, Immunodeficiency 14
- R38R (p.Arg38Arg), rs767121276, gnomAD 1-9710569-C-T, CADD 9.84
- N39H (p.Asn39His), gnomAD 1-9710570-A-C, REVEL 0.33, CADD 23.70
- N39S (p.Asn39Ser), gnomAD 1-9710571-A-G, REVEL 0.10, CADD 20.80
- N39N (p.Asn39Asn), gnomAD 1-9710572-T-C, CADD 10.50
- A40T (p.Ala40Thr), gnomAD 1-9710573-G-A, REVEL 0.33, CADD 24.80
- N41H (p.Asn41His), rs1647005150, ClinGen CA338299610, ClinVar RCV001213349, Ensembl rs1647005150, AlphaMissense 0.09, MetaLR 0.29, Uncertain significance, Immunodeficiency 14
- N41T (p.Asn41Thr), gnomAD rs1223183330, REVEL 0.10, CADD 20.00
- N41S (p.Asn41Ser), gnomAD 1-9710577-A-G, REVEL 0.14, CADD 22.00
- N41N (p.Asn41Asn), gnomAD 1-9710578-C-T, CADD 8.94
- L42F (p.Leu42Phe), TOPMed rs1647005373, Uncertain significance, Immunodeficiency 14
- L42L (p.Leu42Leu), rs1263794275, gnomAD 1-9710581-C-T, CADD 10.90
- S43R (p.Ser43Arg), gnomAD rs1647005617
- S43G (p.Ser43Gly), gnomAD 1-9710582-A-G, REVEL 0.14, CADD 22.10
- T44T (p.Thr44Thr), rs1300275616, gnomAD 1-9710587-C-A, CADD 10.50
- I45V (p.Ile45Val), rs2524692371, ClinGen CA338299639, ClinVar RCV004503877, REVEL 0.53, CADD 25.50, Uncertain significance, Inborn genetic diseases
- K46K (p.Lys46Lys), rs749939527, gnomAD 1-9710593-G-A, CADD 10.30
- Q47R (p.Gln47Arg), gnomAD 1-9710595-A-G, REVEL 0.17, CADD 24.20
- L48L (p.Leu48Leu), gnomAD 1-9715541-C-T, CADD 14.40
- L49V (p.Leu49Val), gnomAD 1-9715544-C-G, REVEL 0.14, CADD 12.20
- L49L (p.Leu49Leu), gnomAD 1-9715544-C-T, CADD 6.86
- H51N (p.His51Asn), NCI-TCGA TCGA novel, REVEL 0.10, CADD 19.10, Variant assessed as somatic; moderate impact.
- H51P (p.His51Pro), Ensembl rs1570356518
- R52C (p.Arg52Cys), TOPMed rs1375117381, gnomAD rs1375117381, REVEL 0.42, CADD 26.60
- R52H (p.Arg52His), rs772851443, ClinGen CA576803, ClinVar RCV001240551, ClinVar RCV004812390, REVEL 0.12, CADD 22.10, Likely benign
- R52S (p.Arg52Ser), gnomAD 1-9715548-G-GGCAC, CADD 31.00
- R52R (p.Arg52Arg), rs558577650, gnomAD 1-9715555-C-T, CADD 1.12
- A53T (p.Ala53Thr), rs766440014, NCI-TCGA Cosmic COSV6312, cosmic curated COSV63128, ExAC rs766440014, REVEL 0.60, CADD 29.50, Variant assessed as somatic; moderate impact.
- A53A (p.Ala53Ala), gnomAD 1-9715558-C-T, CADD 9.44
- Q54R (p.Gln54Arg), gnomAD 1-9715560-A-G, REVEL 0.09, CADD 22.50
- Y55C (p.Tyr55Cys), rs576937504, ClinGen CA338299866, ClinVar RCV003018636, AlphaMissense 0.12, MetaLR 0.19, Uncertain significance, Immunodeficiency 14
- Y55D (p.Tyr55Asp), rs2524802135, ClinGen CA338299864, ClinVar RCV003583382, Uncertain significance, Immunodeficiency 14
- Y55F (p.Tyr55Phe), 1000Genomes rs576937504, ExAC rs576937504, TOPMed rs576937504, gnomAD rs576937504, REVEL 0.07, AlphaMissense 0.12
- Y55Y (p.Tyr55Tyr), gnomAD 1-9715564-T-C, CADD 6.74
- E56Q (p.Glu56Gln), gnomAD 1-9715565-G-C, REVEL 0.23, CADD 24.20
- E56E (p.Glu56Glu), gnomAD 1-9715567-G-A, CADD 12.30
- P57P (p.Pro57Pro), rs373365253, gnomAD 1-9715570-G-A, CADD 7.05
- L58F (p.Leu58Phe), gnomAD 1-9715571-C-T, REVEL 0.29, CADD 18.50
- L58L (p.Leu58Leu), rs1286977475, gnomAD 1-9715573-C-T, CADD 9.59
- H60P (p.His60Pro), rs1425252070, gnomAD 1-9715575-T-TC, CADD 32.00
- M61V (p.Met61Val), rs1057524823, ClinGen CA16603713, ClinVar RCV000418140, Ensembl rs1057524823, REVEL 0.16, CADD 20.40, Uncertain significance, not provided
- M61R (p.Met61Arg), gnomAD 1-9715581-T-G, REVEL 0.43, MetaLR 0.20
- L62H (p.Leu62His), gnomAD 1-9715578-A-ACATG, CADD 27.50
- L62L (p.Leu62Leu), gnomAD 1-9715585-C-T, CADD 12.80
- S63W (p.Ser63Trp), rs769308423, gnomAD 1-9715585-CAG-C, CADD 27.70
- G64V (p.Gly64Val), gnomAD 1-9715590-G-T, REVEL 0.18, MetaLR 0.18
- G64G (p.Gly64Gly), rs1351839783, gnomAD 1-9715591-C-A, CADD 12.40
- P65P (p.Pro65Pro), rs752425885, gnomAD 1-9715594-C-G, CADD 7.46
- E66K (p.Glu66Lys), NCI-TCGA Cosmic COSV6313, cosmic curated COSV63130, REVEL 0.29, CADD 24.00, Variant assessed as somatic; moderate impact.
- A67T (p.Ala67Thr), ExAC rs757517500, gnomAD rs757517500, REVEL 0.16, CADD 24.60
- A67S (p.Ala67Ser), gnomAD 1-9715598-G-T, REVEL 0.17, MetaLR 0.15
- Y68H (p.Tyr68His), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10074, Variant assessed as somatic; moderate impact.
- Y68L (p.Tyr68Leu), rs1319488447, gnomAD 1-9715600-C-CT, CADD 32.00
- Y68C (p.Tyr68Cys), gnomAD 1-9715600-CTA-C, CADD 32.00
- Y68Y (p.Tyr68Tyr), rs781328697, gnomAD 1-9715603-T-C, CADD 2.83
- T71P (p.Thr71Pro), Ensembl rs1570356775
- C72C (p.Cys72Cys), gnomAD 1-9715615-C-T, CADD 8.52
- I73V (p.Ile73Val), cosmic curated COSV10074, ExAC rs745980735, gnomAD rs745980735, REVEL 0.12, CADD 15.20
- I73I (p.Ile73Ile), gnomAD 1-9715618-C-T, CADD 12.80
- I73M (p.Ile73Met), gnomAD 1-9715618-C-G, REVEL 0.48, MetaLR 0.54
- N74S (p.Asn74Ser), rs1043386158, ClinGen CA17773325, ClinVar RCV001237606, ClinVar RCV005410929, REVEL 0.27, CADD 22.00, Likely benign
- N74K (p.Asn74Lys), gnomAD 1-9715620-ACC-A, CADD 25.80
- Q75H (p.Gln75His), gnomAD 1-9715624-G-C, REVEL 0.24, MetaLR 0.39
- T76A (p.Thr76Ala), gnomAD 1-9715625-A-G, REVEL 0.17, MetaLR 0.29
- A77V (p.Ala77Val), rs1570356857, ClinGen CA338300144, cosmic curated COSV63128, ClinVar RCV003070557, REVEL 0.58, CADD 25.20, Uncertain significance, Immunodeficiency 14
- A77A (p.Ala77Ala), rs756139699, gnomAD 1-9715630-G-A, CADD 0.84
- E78D (p.Glu78Asp), rs1647287735, ClinGen CA338300151, ClinVar RCV003400003, Uncertain significance, PIK3CD-related disorder
- E78K (p.Glu78Lys), rs1647287408, ClinGen CA338300147, ClinVar RCV003397758, TOPMed rs1647287408, AlphaMissense 0.23, MetaLR 0.42, Uncertain significance, PIK3CD-related disorder
- E78G (p.Glu78Gly), gnomAD 1-9715629-C-CG, CADD 26.60
- Q79R (p.Gln79Arg), Ensembl rs1557659457, REVEL 0.08, CADD 17.30
- Q79Q (p.Gln79Gln), rs1203000902, gnomAD 1-9715636-G-A, CADD 10.40
- Q80R (p.Gln80Arg), gnomAD 1-9715638-A-G, REVEL 0.36, MetaLR 0.31
- E81Q (p.Glu81Gln), gnomAD rs1253851300, REVEL 0.63, CADD 27.60
- E81K (p.Glu81Lys), gnomAD 1-9715640-G-A, REVEL 0.66, MetaLR 0.65
- E83Q (p.Glu83Gln), ESP rs377713059, ExAC rs377713059, gnomAD rs377713059, REVEL 0.27, CADD 25.10
- D84N (p.Asp84Asn), gnomAD 1-9715649-G-A, REVEL 0.67, MetaLR 0.71
- D84D (p.Asp84Asp), rs755377648, gnomAD 1-9715651-C-T, CADD 2.98
- R87Q (p.Arg87Gln), cosmic curated COSV10650, Ensembl rs1557659523, REVEL 0.59, CADD 26.00
- R87W (p.Arg87Trp), rs768486795, ClinGen CA17773395, cosmic curated COSV10969, ClinVar RCV001312599, REVEL 0.67, CADD 26.30, Uncertain significance
- R88C (p.Arg88Cys), rs1557659540, ClinGen CA338300219, NCI-TCGA Cosmic COSV6312, cosmic curated COSV63127, REVEL 0.63, CADD 26.50, Uncertain significance, Inborn genetic diseases; Immunodeficiency 14
- R88H (p.Arg88His), rs769029561, NCI-TCGA Cosmic COSV6313, cosmic curated COSV63132, ExAC rs769029561, REVEL 0.82, CADD 28.60, Variant assessed as somatic; moderate impact.
- R88S (p.Arg88Ser), TOPMed rs1557659540, gnomAD rs1557659540, Uncertain significance
- R88R (p.Arg88Arg), gnomAD 1-9715663-T-A, CADD 9.66
- L89R (p.Leu89Arg), rs2524804604, ClinGen CA2582341889, ClinVar RCV003333529, Likely pathogenic
- L89L (p.Leu89Leu), rs932680235, gnomAD 1-9715666-G-A, CADD 7.87
- C90* (p.Cys90Ter), ExAC rs775052663, gnomAD rs775052663, CADD 29.80
- C90A (p.Cys90Ala), gnomAD 1-9715658-C-CGGCG, CADD 31.00
- D91D (p.Asp91Asp), rs1647292774, gnomAD 1-9715672-C-T, CADD 12.60
- V92M (p.Val92Met), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10073, Ensembl rs1647293076, REVEL 0.53, CADD 24.10, Variant assessed as somatic; moderate impact.
- V92L (p.Val92Leu), gnomAD 1-9715673-G-T, REVEL 0.12, MetaLR 0.22
- V92V (p.Val92Val), gnomAD 1-9715675-G-A, CADD 8.78
- Q93H (p.Gln93His), gnomAD 1-9715678-G-T, REVEL 0.43, MetaLR 0.33
- P94P (p.Pro94Pro), gnomAD 1-9715681-C-T, CADD 13.70
- L96P (p.Leu96Pro), gnomAD 1-9715683-T-TC, CADD 31.00
- L96L (p.Leu96Leu), rs774791238, gnomAD 1-9715685-C-T, CADD 12.80
- P97S (p.Pro97Ser), TOPMed rs1167794081, gnomAD rs1167794081, REVEL 0.47, CADD 23.20
- P97A (p.Pro97Ala), gnomAD 1-9715688-C-G, REVEL 0.45, MetaLR 0.52
- P97P (p.Pro97Pro), gnomAD 1-9715690-C-A, CADD 1.42
- V98I (p.Val98Ile), rs150205370, ClinGen CA576823, cosmic curated COSV63127, ClinVar RCV003151599, REVEL 0.09, CADD 21.90, Uncertain significance, not specified
- V98F (p.Val98Phe), gnomAD 1-9715691-G-T, REVEL 0.25, MetaLR 0.22
- L99L (p.Leu99Leu), rs760378876, gnomAD 1-9715694-C-T, CADD 11.60
- L99V (p.Leu99Val), gnomAD 1-9715694-C-G, REVEL 0.68, MetaLR 0.71
- R100H (p.Arg100His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R100L (p.Arg100Leu), ExAC rs766022415, gnomAD rs766022415, REVEL 0.60, CADD 26.20
- R100C (p.Arg100Cys), gnomAD 1-9715697-C-T, REVEL 0.57, MetaLR 0.48
- R100R (p.Arg100Arg), gnomAD 1-9715699-C-T, CADD 13.20
- L101L (p.Leu101Leu), rs1283019119, gnomAD 1-9715700-C-T, CADD 13.60
- V102M (p.Val102Met), rs1647296006, ClinGen CA338300302, ClinVar RCV002006190, ClinVar RCV006458851, REVEL 0.52, CADD 29.20, Uncertain significance, Immunodeficiency 14; not specified
- V102V (p.Val102Val), rs1376334251, gnomAD 1-9715705-G-A, CADD 13.30
- A103T (p.Ala103Thr), rs1229729609, ClinGen CA338300308, cosmic curated COSV10074, ClinVar RCV003404252, REVEL 0.09, CADD 21.30, Uncertain significance, PIK3CD-related disorder; Immunodeficiency 14
- R104C (p.Arg104Cys), rs1315288471, ClinGen CA338300316, ClinVar RCV002583814, TOPMed rs1315288471, REVEL 0.55, CADD 29.30, Uncertain significance, Immunodeficiency 14
- R104H (p.Arg104His), ExAC rs776273008, TOPMed rs776273008, gnomAD rs776273008, REVEL 0.61, CADD 32.00
- R104L (p.Arg104Leu), ExAC rs776273008, TOPMed rs776273008, gnomAD rs776273008, REVEL 0.65, CADD 32.00
- R104G (p.Arg104Gly), gnomAD 1-9715709-C-G, REVEL 0.58, MetaLR 0.62
- E105* (p.Glu105Ter), rs1557659696, gnomAD 1-9715710-G-GT, CADD 32.00
- G106D (p.Gly106Asp), gnomAD rs1225852287, REVEL 0.34, CADD 25.00
- G106S (p.Gly106Ser), cosmic curated COSV10074, TOPMed rs1647298126, gnomAD rs1647298126, REVEL 0.26, CADD 24.40
- G106G (p.Gly106Gly), rs1343448421, gnomAD 1-9715717-C-G, CADD 3.25
- D107E (p.Asp107Glu), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10074, Variant assessed as somatic; moderate impact.
- D107G (p.Asp107Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- D107N (p.Asp107Asn), cosmic curated COSV63132, ExAC rs759579609, TOPMed rs759579609, gnomAD rs759579609, REVEL 0.06, CADD 23.50
- D107R (p.Asp107Arg), rs2524805817, ClinVar RCV004560507, Likely pathogenic
- D107D (p.Asp107Asp), rs1017772805, gnomAD 1-9715720-C-T, CADD 12.70
- R108C (p.Arg108Cys), rs1205317546, ClinGen CA338300341, ClinVar RCV001822704, ClinVar RCV002542681, REVEL 0.30, CADD 25.40, Uncertain significance
- R108H (p.Arg108His), ExAC rs765031777, TOPMed rs765031777, gnomAD rs765031777, REVEL 0.30, CADD 25.80, Uncertain significance, not provided
- R108L (p.Arg108Leu), rs765031777, ClinGen CA576828, cosmic curated COSV63130, ClinVar RCV000788952, REVEL 0.25, CADD 25.40, Uncertain significance, Immunodeficiency 14
Public PIK3CD analysis runs
- PIK3CD analysis run — PIK3CD (1,087 variants) — completed 2026-08-18